Articles

Binding and conformation of dendrimer-based drug delivery systems: a molecular dynamics study

  • Fa-Da Zhang ,
  • Yi Liu ,
  • Jing-Cheng Xu ,
  • Sheng-Juan Li ,
  • Xiu-Nan Wang ,
  • Yue Sun ,
  • Xin-Luo Zhao
Expand
  • 1 Department of Physics and Materials Genome Institute, Shanghai University, Shanghai 200444, P. R. China;
    2 School of Materials Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, P. R. China;
    3 School of Energy & Power Engineering, University of Shanghai for Science and Technology, Shanghai 200093, P. R. China

Received date: 2015-05-15

  Revised date: 2015-08-16

  Online published: 2015-09-22

Supported by

The authors are grateful for financial supports from “Shanghai Pujiang Talent” program (Grant No. 12PJ1406500), “Shanghai High-tech Area of Innovative Science and Technology (Grant No. 14521100602)”, STCSM; “Key Program of Innovative Scientific Research” (Grant No. 14ZZ130) and “Key Laboratory of Advanced Metal-based Electrical Power Materials”, the Education Commission of Shanghai Municipality; State Key Laboratory of Heavy Oil Processing, China University of Petroleum (Grant No. SKLOP201402001); National Natural Science Foundation of China (Grant Nos. 51202137, 61240054, and 11274222).

Abstract

All atomistic molecular dynamics simulations were performed on poly (amidoamine) (PAMAM) dendrimers that compound non-covalently with anticancer drug molecules including DOX, MTX, CE6, and SN38. The binding energies as well as their associated interaction energies and deformation energies were combined to evaluate the relative binding strength among drug, PAMAM, and PEG chains. We find that the deformation of dendrimers due to drug loading plays a crucial role in the drug binding. It is energetically favorable for the drug molecules to bind with PAMAM while the drugs bind with PEG metastable chains via kinetic confinement. Surface PEGylation helps dendrimers to accommodate more drug molecules with greater strength without inducing too much expansion. This work indicates that tuning the functionalized terminal groups of dendrimers is critical to design efficient dendrimer-based drug delivery systems.

Cite this article

Fa-Da Zhang , Yi Liu , Jing-Cheng Xu , Sheng-Juan Li , Xiu-Nan Wang , Yue Sun , Xin-Luo Zhao . Binding and conformation of dendrimer-based drug delivery systems: a molecular dynamics study[J]. Advances in Manufacturing, 2015 , 3(3) : 221 -231 . DOI: 10.1007/s40436-015-0120-7

References

1. Menjoge AR, Kannan RM, Tomalia DA (2010) Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 15(5):171-185

2. Tomalia DA, Baker H, Dewald J et al (1985) A new class of polymers: starburst-dendritic macromolecules. Polym J 17(1):117-132

3. Kolhe P, Misra E, Kannan RM et al (2003) Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 259(1):143-160

4. Zhang YH, Thomas TP, Lee KH et al (2011) Polyvalent saccharide- functionalized generation 3 poly(amidoamine) dendrimer- methotrexate conjugate as a potential anticancer agent. Bioorgan Med Chem 19(8):2557-2564

5. Kurtoglu YE, Mishra MK, Kannan S et al (2010) Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int J Pharm 384(1):189-194

6. Wiener EC, Brechbiel MW, Brothers H et al (1994) Dendrimerbased metal-chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med 31(1):1-8

7. Kobayashi H, Saga T, Kawamoto S et al (2001) Dynamic micromagnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd) 64. Cancer Res 61(13):4966-4970

8. Majoros IJ, Williams CR, Baker JR (2008) Current dendrimer applications in cancer diagnosis and therapy. Curr Top Med Chem 8(14):1165-1179

9. Lee CC, MacKay JA, Frechet JMJ et al (2005) Designing dendrimers for biological applications. Nat Biotechnol 23(12): 1517-1526

10. Esfand R, Tomalia DA (2001) Poly (amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 6(8):427-436

11. Kavyani S, Amjad-Iranagh S, Modarress H (2014) Aqueous poly(amidoamine) dendrimer G3 and G4 generations with several interior cores at pHs 5 and 7: a molecular dynamics simulation study. J Phys Chem B 118(12):3257-3266

12. Mignani S, El Kazzouli S, Bousmina M et al (2013) Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev 65(10):1316-1330

13. Svenson S, Tomalia DA (2012) Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 64(1):102-105

14. Tomalia DA, Naylor AM, Goddard WA (1990) Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter. Angew Chem Int Edit 29(2):138-175

15. Yabbarov NG, Posypanova GA, Vorontsov EA et al (2013) Targeted delivery of doxorubicin: drug delivery system based on PAMAM dendrimers. Biochemistry (Moscow) 78(8):884-894

16. Chang YL, Liu N, Chen L et al (2012) Synthesis and characterization of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery. J Mater Chem 22(19):9594-9601

17. Wang Y, Cao XY, Guo R et al (2011) Targeted delivery of doxorubicin into cancer cells using a folic acid-dendrimer conjugate. Polym Chem 2(8):1754-1760

18. Chang YL, Li YP, Meng XL et al (2013) Dendrimer functionalized water soluble magnetic iron oxide conjugates as dual imaging probe for tumor targeting and drug delivery. Polym Chem 4(3):789-794

19. Majoros IJ, Myc A, Thomas T et al (2006) PAMAM dendrimerbased multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7(2):572-579

20. Rekas A, Lo V, Gadd GE et al (2009) PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein. Macromol Biosci 9(3):230-238

21. Kang H, DeLong R, Fisher MH et al (2005) Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 22(12):2099-2106

22. Majoros IJ, Thomas TP, Mehta CB et al (2005) Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 48(19):5892-5899

23. Wang W, Xiong W, Zhu YH et al (2010) Protective effect of PEGylation against poly(amidoamine) dendrimer-induced hemolysis of human red blood cells. J Biomed Mater Res B 93B(1):59-64

24. He H, Li Y, Jia XR et al (2011) PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 32(2):478-487

25. Sideratou Z, Kontoyianni C, Drossopoulou GI et al (2010) Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system. Bioorg Med Chem Lett 20(22):6513-6517

26. Singh P, Gupta U, Asthana A et al (2008) Folate and folate-PEGPAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 19(11):2239-2252

27. Isakau HA, Parkhats MV, Knyukshto VN et al (2008) Toward understanding the high PDT efficacy of chlorine6- polyvinylpyrrolidone formulations: photophysical and molecular aspects of photosensitizer-polymer interaction in vitro. J Photochem Photobiol B 92(3):165-174

28. Goldberg DS, Vijayalakshmi N, Swaan PW et al (2011) G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J Control Release 150(3):318-325

29. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303(5665):1818-1822

30. Tian WD, Ma YQ (2012) pH-responsive dendrimers interacting with lipid membranes. Soft Matter 8(9):2627-2632

31. Maingi V, Kumar MVS, Maiti PK (2012) PAMAM dendrimer- drug interactions: effect of pH on the binding and release pattern. J Phys Chem B 116(14):4370-4376

32. Crampton HL, Simanek EE (2007) Dendrmers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. Polym Int 56(4):489-496

33. Kwon IK, Lee SC, Han B et al (2012) Analysis on the current status of targeted drug delivery to tumors. J Control Release 164(2):108-114

34. Karatasos K, Krystallis M (2009) Dynamics of counterions in dendrimer polyelectrolyte solutions. J Chem Phys 130(11):1-11

35. Zhong TP, Ai PF, Zhou J (2011) Structures and properties of PAMAM dendrimer: a multi-scale simulation study. Fluid Phase Equilib 302(1):43-47

36. Liu Y, Bryantsev VS, Diallo MS et al (2009) PAMAM dendrimers undergo pH responsive conformational changes without swelling. J Am Chem Soc 131(8):2798-2799
Outlines

/